上海交通大学医学院附属仁济医院
Renji Hospital
在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
上海交通大学医学院附属仁济医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma2 篇牵头论文牵头 2 项开放试验
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文牵头 1 项开放试验
- 肝细胞癌Hepatocellular carcinoma104 篇牵头论文牵头 5 项开放试验
- 胃癌Stomach cancer65 篇牵头论文牵头 5 项开放试验
- 肝母细胞瘤Hepatoblastoma3 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma3 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour10 篇牵头论文
- 神经母细胞瘤Neuroblastoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma24 篇牵头论文牵头 2 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
- 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder11 篇牵头论文牵头 1 项开放试验
- IgG4相关性疾病IgG4-related disease2 篇牵头论文
- 重症肌无力Myasthenia gravis3 篇牵头论文牵头 1 项开放试验
- 胆道闭锁Biliary atresia3 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
- 大动脉炎Takayasu arteritis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
- 法布雷病Fabry disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
- 白塞病Behçet disease2 篇牵头论文
- IgA 肾病IgA nephropathy6 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis17 篇牵头论文牵头 1 项开放试验
- 原发性硬化性胆管炎Primary sclerosing cholangitis5 篇牵头论文
- 遗传性血管性水肿Hereditary angioedema2 篇牵头论文
未列出的收录疾病:尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 10 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Trop2-targeted immunoPET Imaging of Solid Tumors
- 分期
- II/III期
- 开始
- 2024-12
- 登记号
- NCT06851663
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募CD70-targeted immunoPET Imaging of Malignant Cancers
- 分期
- II期
- 开始
- 2024-12
- 登记号
- NCT06852638
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)4
- DTL promotes glycolysis and tumor progression in nasopharyngeal carcinoma cells by degrading KAT2B and activating the PI3K/AKT/mTOR pathway
- Additional file 4 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
- Additional file 6 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma
- Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- 分期
- 不分期
- 开始
- 2026-09
- 登记号
- NCT07769866
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- 分期
- I期
- 开始
- 2024-07
- 登记号
- NCT06465069
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、广州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation.
- Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
- FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.
- Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases.
- The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy.
- Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.
- Circular RNA hsa_circ_0003823 promotes the Tumor Progression, Metastasis and Apatinib Resistance of Esophageal Squamous Cell Carcinoma by miR-607/CRISP3 Axis.
- Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
- NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
- Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
- Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)6
- The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.
- P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study
- 70P A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs)
- APEC: Efficacy and toxicity of anlotinib plus PD-1 inhibitors as later-line therapy in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A retrospective real-world study.
- Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 104 篇,占 0.7%。
上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募FGF19 Overexpression Combination Unified Study in HCC-19
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06978933
年龄 18 岁 至 未注明(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- 分期
- IV期
- 开始
- 2024-10
- 登记号
- NCT06353126
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2024-08
- 登记号
- NCT06519578
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2023-01
- 登记号
- NCT05926726
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 即将招募HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- 分期
- 未注明
- 开始
- 2025-08
- 登记号
- NCT07045558
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07327034
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文104
- Oridonin induces ferroptosis by inhibiting ubiquitin-mediated degradation of HMOX1 in hepatocellular carcinoma.
- A therapeutic strategy integrating ultrasound-guided microwave ablation with nanocomposite hydrogels to enhance autophagy and suppress tumor growth in hepatocellular carcinoma.
- Cardiorespiratory fitness-associated gene signature for prognosis in hepatocellular Carcinoma: Computational prediction and in vivo validation.
- Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.
- Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2-mediated increase of SOAT2 RNA methylation.
- Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.
- Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma.
- PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.
- Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.
- Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation.
- DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.
- PRMT1-mediated modification of H4R3me2a promotes liver cancer progression by enhancing the transcriptional activity of SOX18.
- Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.
- Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.
- SNX17 mediates STAT3 activation to promote hepatocellular carcinoma progression via a retromer dependent mechanism.
- Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
- The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.
- GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.
- Upregulation of EFCAB7 after radiofrequency ablation promoting hepatocellular carcinoma metastasis and survival by regulating PARK7.
- Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy.
- CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.
- SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1.
- Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy.
- TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.
- Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
- DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
- UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
- Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
- NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression.
- Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.
- Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
- PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
- Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?
- UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis.
- Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma.
- Zbtb7b defines a compensatory mechanism in MASLD-related HCC progression by suppressing H19-mediated hepatic lipid deposition.
- Identification and validation of a prognostic model based on four genes related to satellite nodules in hepatocellular carcinoma.
- Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.
- Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism.
- GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.
- A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.
- Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma.
- ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
- Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.
- Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.
- Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.
- The negative effect of G1958A polymorphism on MTHFD1 protein stability and HCC growth.
- KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
- PET imaging of tumor vascular normalization in hepatocellular carcinoma.
- Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
- Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
- Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
- Nucleolar HEAT Repeat Containing 1 Up-regulated by the Mechanistic Target of Rapamycin Complex 1 Signaling Promotes Hepatocellular Carcinoma Growth by Dominating Ribosome Biogenesis and Proteome Homeostasis.
- Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
- Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention.
- Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis.
- Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma.
- A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.
- RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma.
- hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
- CCBE1 promotes mitochondrial fusion by inhibiting the TGFβ-DRP1 axis to prevent the progression of hepatocellular carcinoma.
- AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.
- Evolving therapeutic landscape of advanced hepatocellular carcinoma.
- STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice.
- Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma.
- Aggregation-Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-Guided siRNA Therapy of Hepatocellular Carcinoma.
- Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
- Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin.
- Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.
- ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma.
- GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
- Crucial role of T cells in NAFLD-related disease: A review and prospect.
- Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.
- Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer.
- A pre‑clinical model combining cryopreservation technique with precision‑cut slice culture method to assess the in vitro drug response of hepatocellular carcinoma.
- Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation.
- STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1.
- CaCO3 -Encapuslated Microspheres for Enhanced Transhepatic Arterial Embolization Treatment of Hepatocellular Carcinoma.
- Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen.
- Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.
- Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma.
- XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma.
- NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis.
- A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
- MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma.
- Inhibition of AMPK activity by TRIM11 facilitates cell survival of hepatocellular carcinoma under metabolic stress.
- A cascade-network framework for integrated registration of liver DCE-MR images.
- Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma.
- Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis.
- Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis.
- Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
- Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
- Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes.
- The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
- Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study.
- C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment.
- ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.
- Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
- Identification of the Different Gene Expression Characteristics from Liver Cirrhosis to Hepatocellular Carcinoma Using Single-Cell Sequencing Analyses.
- An antibody-free liver cancer screening approach based on nanoplasmonics biosensing chips via spectrum-based deep learning.
- EGFR activation limits the response of liver cancer to lenvatinib.
- Exploring liver cancer biology through functional genetic screens.
- Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
- FGF19 Overexpression Combination Unified Study in HCC-19
- HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
- DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
- Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
- Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
- Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy
- CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
- Clinical and Basic Study for Pediatric Liver Transplantation
- Anti-GPC3 CAR T for Treating Patients With Advanced HCC
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- IMC001 for Clinical Research on Advanced Digestive System Malignancies
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Chimeric Antigen Receptor T Cells Targeting Glypican-3
- NeuWave Microwave Ablation HCC China Study
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
- A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 65 篇,占 0.7%。
上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 12
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募ImmunoPET Imaging of Pancreatic Cancer
- 分期
- 不分期
- 开始
- 2024-11
- 登记号
- NCT06602037
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募Target-specific immunoPET Imaging of Digestive System Carcinoma
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06715839
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- 分期
- 不分期
- 开始
- 2023-12
- 登记号
- NCT06081647
年龄 18 岁 至 60 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院;另有 7 家列出的医院为研究中心上海、南京、南昌、杭州、济南
- 正在招募Atrophic Gastritis Predicts the Risk of Gastric Cancer
- 分期
- 未注明
- 开始
- 2023-12
- 登记号
- NCT06203327
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 即将招募Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- 分期
- II期
- 开始
- 2024-08
- 登记号
- NCT06531291
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06901531
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、郑州
- 正在招募Bovine Reinforcement in Stomach, Colorectal and Lung Operation
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06968221
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2025-07
- 登记号
- NCT07066657
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙
- 正在招募Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07366528
年龄 18 岁 至 80 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海
- 正在招募A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- 分期
- III期
- 开始
- 2024-11
- 登记号
- NCT06532006
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛
- 即将招募AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- 分期
- 未注明
- 开始
- 2026-09
- 登记号
- NCT07782294
年龄 18 岁 至 75 岁(登记的条件)
牵头:浙江大学医学院附属第二医院;另有 2 家列出的医院为研究中心上海、安阳、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文65
- Bi-phase CT radiomics nomogram for the preoperative prediction of pylorus lymph node metastasis in non-pyloric gastric cancer patients.
- Long-term outcomes and quality of life of laparoscopic-assisted pylorus-preserving gastrectomy compared to laparoscopic-assisted distal gastrectomy with billroth I anastomosis for early gastric cancer(pT1N0M0): A Randomized Controlled Trial
- Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.
- Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial.
- Metabolic fingerprinting enables rapid, label-free histopathology in gastric cancer diagnosis and prognostic prediction.
- Nuclear translocation of CDK5RAP3 regulated by NXF3 promotes the progression of gastric cancer.
- Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.
- High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer.
- CST1 promoted gastric cancer development by activating the AKT pathway.
- Automated interpretation of PD-L1 CPS based on multi-AI models integration strategy in gastric cancer.
- Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study.
- Clinicopathological Characteristics of Gastric Cancer in China: A 16-Year Single-Center Retrospective Clinical Study.
- A machine learning-enhanced gastric cancer diagnostic method based on shell-isolated nanoparticle-enhanced Raman spectroscopy.
- DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer.
- Renji endoscopic submucosal dissection video data set for early gastric cancer.
- A Retrospective Study of Laparoscopic Distal Gastrectomy Guided by Carbon Nanoparticle Suspension Injection Lymphography for Gastric Cancer.
- Comprehensive exome profiling identifies ARHGEF12 mutation as a driver in gastric cancer with ovarian metastasis.
- Effectiveness of circulating tumor cells and circulating tumor DNA in peritoneal lavage fluid for predicting metachronous peritoneal metastasis of gastric cancer.
- Total laparoscopy-assisted total gastrectomy with Da Vinci robotic system conducted by robotic enhanced neurocomputing joint intelligence gastrointestinal surgery hub (RENJI-GISH): a preliminary clinical study and case report.
- Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.
- Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective si
- Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.
- Circadian system disorder induced by aberrantly activated EFNB2-EPHB2 axis leads to facilitated liver metastasis in gastric cancer.
- Single-cell RNA transcriptomic analyses of tumor microenvironment of ovarian metastasis in gastric cancer.
- Serum Circulating mRNA Panel for the Early Detection of Gastric Cancer: A Potential Biomarker Test.
- ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
- [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs.
- Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism.
- Effectiveness and safety of Moluodan in the treatment of precancerous lesions of gastric cancer: A randomized clinical trial.
- Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment.
- Targeting cellular senescence as a therapeutic vulnerability in gastric cancer.
- DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.
- CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.
- SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function.
- Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
- MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway.
- The SLITRK4-CNPY3 axis promotes liver metastasis of gastric cancer by enhancing the endocytosis and recycling of TrkB in tumour cells.
- Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.
- Gastric metastasis from renal cell carcinoma 13 years after nephrectomy.
- First Total-Body Kinetic Modeling and Parametric Imaging of Dynamic 68Ga-FAPI-04 PET in Pancreatic and Gastric Cancer.
- Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer.
- Delivery of LINC00589 via mesoporous silica nanoparticles inhibits peritoneal metastasis in gastric cancer.
- Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer.
- Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer.
- Synchronous in situ follicular neoplasia with MALT lymphoma and intramucosal adenocarcinoma in the stomach: A case report.
- Trends of stomach cancer survival: A systematic review of survival rates from population-based cancer registration.
- Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.
- Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH-Sensitive Nano Platform.
- Plasmonic Alloys Reveal a Distinct Metabolic Phenotype of Early Gastric Cancer.
- Tea Drinking and Risk of Cancer Incidence: A Meta-Analysis of Prospective Cohort Studies and Evidence Evaluation.
- Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
- Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings.
- Stomach-specific c-Myc overexpression drives gastric adenoma in mice through AKT/mammalian target of rapamycin signaling.
- CHPF promotes gastric cancer tumorigenesis through the activation of E2F1.
- ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression.
- mTOR signaling regulates gastric epithelial progenitor homeostasis and gastric tumorigenesis via MEK1-ERKs and BMP-Smad1 pathways.
- The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.
- Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value.
- Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.
- Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy.
- Diagnostic endoscopic submucosal dissection in the diagnosis of biopsy-missed gastric mucosa-associated lymphoid tissue lymphoma.
- Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer.
- Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.
- Poorly differentiated is more significant than signet ring cell component for lymph node metastasis in mixed-type early gastric cancer: a retrospective study from a large-volume hospital.
- Sema3C promotes hepatic metastasis and predicts poor prognosis in gastric adenocarcinoma.
中文论文(未计入)8
- [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].
- [Thinking and strategy selection on the quality control of early gastric cancer].
- [Statistical analysis of disability-adjusted life years for stomach and colorectal cancers in Changning District of Shanghai].
- [Multiple primary malignancies combined with SWI/SNF complex-deficient gastric cancer: a case report and literature review].
- [Influence of postoperative complications on prognosis of gastric cancer-The manifestation of gastric surgeon's skill, responsibility and empathy].
- [Current status and progression of minimally invasive surgery after neoadjuvant therapy for adenocarcinoma of esophagogastric junction].
- [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].
- [Choice of function-preserving gastrectomy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)43
- Target-specific immunoPET Imaging of Digestive System Carcinoma
- Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- ImmunoPET Imaging of Pancreatic Cancer
- The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
- A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
- Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
- Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
- Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
- HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
- HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
- Anxiety Before Non-cardiac Surgery in Adults
- Nasal Mask Kit in Gastrointestinal Endoscopy
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Sedated Gastrointestinal Endoscopes in Obesity
- Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy
- Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
- Safety and Feasibility of Reversible Induction Strategy
- Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients
- A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
- Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
- High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol
- Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric Cancer
- WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
- Adverse Events During Upper Gastrointestinal Endoscopy
- Atrophic Gastritis Predicts the Risk of Gastric Cancer
- Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy
- Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Bovine Reinforcement in Stomach, Colorectal and Lung Operation
- Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- IMC001 for Clinical Research on Advanced Digestive System Malignancies
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma.
- Pediatric Hepatoblastoma After Neoadjuvant Chemotherapy: Diagnostic Performance of MR in Staging POSTTEXT and Vascular Involvement.
- Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma.
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 11 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文3
- Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.
- Deciphering the role of lipid metabolism and acetylation in osteosarcoma: A comprehensive molecular analysis.
- Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws.
早期论文(2016–2020 年)16
- Long noncoding RNA SNHG8 promotes the proliferation of osteosarcoma cells by downregulating miR-542-3p.
- Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells.
- Organoid culture system for patient-derived lung metastatic osteosarcoma.
- MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.
- Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells.
- SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.
- miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.
- MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-β-mediated AKT/GSK-3β/SNAIL-1 signaling.
- Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.
- SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
- Generating lung-metastatic osteosarcoma targeting aptamers for in vivo and clinical tissue imaging.
- Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
- Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis.
- miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway.
- CRL4BDCAF11 E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
- MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.9%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文10
- Development and validation of a machine-learning-based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospective multicenter study.
- Aptamer-based drug delivery for targeted therapy of imatinib-resistant gastrointestinal stromal tumor.
- Identification of D842V mutation in gastrointestinal stromal tumors based on CT radiomics: a multi-center study.
- Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging).
- Prediction of high Ki-67 proliferation index of gastrointestinal stromal tumors based on CT at non-contrast-enhanced and different contrast-enhanced phases.
- Clinical importance of tumor rupture in gastrointestinal stromal tumor.
- Adult Female Patient with Untreated Truncus Arteriosus Type I and Torsion of Small Bowel Gastrointestinal Stromal Tumor: A Rare Case Report.
- Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.
- The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
- Low Distribution of TIM-3+ Cytotoxic Tumor-Infiltrating Lymphocytes Predicts Poor Outcomes in Gastrointestinal Stromal Tumors.
中文论文(未计入)7
- [Long-term prognosis of surgical treatment for peri-gastric cardial gastrointestinal stromal tumors].
- [Prognosis and its influencing factors in patients with non-gastric gastrointestinal stromal tumors at low risk of recurrence: a retrospective multicenter study in China].
- [Rethinking several issues related to surgical treatment for advanced GIST in the era of targeted therapy].
- [Identification and inner relation between gastrointestinal stromal tumor and intra-abdominal desmoid tumor].
- [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].
- [Clinical significance of the deep learning algorithm based on contrast-enhanced CT in the differential diagnosis of gastric gastrointestinal stromal tumors with a diameter ≤ 5 cm].
- [Act following etiquette and change with time: analysis and discussion on the difference between the current guidelines and clinical practice of gastrointestinal stromal tumor].
早期论文(2016–2020 年)15
- Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
- Clinicopathologic characteristics, diagnostic clues, and prognoses of patients with multiple sporadic gastrointestinal stromal tumors: a case series and review of the literature.
- Recurrent Extra-gastrointestinal Stromal Tumor of the Vagina: A Case Report and Review of the Literature.
- [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
- [Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].
- [Pitfalls and dilemmas in the decision-making process of diagnosis and treatment on gastrointestinal stromal tumor].
- Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor.
- [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
- [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
- miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.
- miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth.
- [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
- CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.
- [Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].
- [New challenges in the diagnosis and treatment of gastrointestinal stromal tumor: thinking and practice from evidence-based medicine to precision medicine].
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
- Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
- Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
- Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 1.4%。
上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- 分期
- 不分期
- 开始
- 2024-10
- 登记号
- NCT06594211
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 邀请入组Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- 分期
- 未注明
- 开始
- 2026-11
- 登记号
- NCT07833046
年龄未注明(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2026-04
- 登记号
- NCT07493135
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07555938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛
- 正在招募A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2026-09
- 登记号
- NCT07760454
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、苏州
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文24
- Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma.
- Enhancer Extrachromosomal Circular DNA ANKRD28 Elicits Drug Resistance via POU2F2-Mediated Transcriptional Network in Multiple Myeloma.
- First-line anti-BCMA CAR-T cell therapy in a fragile patient with biclonal gammopathy and giant plasma cell tumor multiple myeloma with multiple comorbidities: a case report.
- Dual roles of IRE1α inhibition in reversing mitochondrial ROS-induced CD8+ T-cell senescence and exerting direct antitumor effects in multiple myeloma.
- Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor.
- Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
- The added diagnostic value of 18 F-FDG PET/CT radiomic analysis in multiple myeloma patients with negative visual analysis.
- From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy.
- Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.
- Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma.
- Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma.
- Metabolic kinetic modeling of [11C]methionine based on total-body PET in multiple myeloma.
- Unravelling the imbalanced Th17-like cell differentiation by single-cell RNA sequencing in multiple myeloma.
- C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.
- Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.
- Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.
- Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma.
- Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.
- Promising therapeutic approaches for relapsed/refractory multiple myeloma.
- Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study.
- Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053.
- Annotating BCMA Expression in Multiple Myelomas.
- ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053.
- Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
中文论文(未计入)3
- [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
- [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
- [Detection of minimal residual disease in patients with multiple myeloma:current status, challenges and prospective].
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
- Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
- Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
- PVd Versus Vd in NDMM Patients With RI
- A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- A Study of Daratumumab
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07208058
年龄 16 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Hemophagocytic lymphohistiocytosis after solid organ transplantation: A challenge for clinicians.
- Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
- Gastric ulcer as the main complication in hemophagocytic lymphohistiocytosis: A case report.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
血液疾病
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 2.3%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 4 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- 分期
- I期
- 开始
- 2024-03
- 登记号
- NCT06249438
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder.
- Telitacicept Inhibits the Maturation and Differentiation of B Lymphocytes in NMOSD.
- Multi-tracer PET and MR imaging visualize distinct metabolic and inflammatory profiles in the white matter of NMOSD and MOGAD.
- Efficacy of human umbilical cord mesenchymal stem cell in the treatment of neuromyelitis optica spectrum disorders: an animal study.
- Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.
- Human NMO-IgG Induced Different Pathological and Immunological Changes in the CNS and Peripheral Tissues of Mice.
- Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.
- Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.
- Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.
- Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.
- Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 4 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- 分期
- I/II期
- 开始
- 2026-01
- 登记号
- NCT07061938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 7 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- 分期
- I期
- 开始
- 2024-03
- 登记号
- NCT06249438
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Interactions Between Extracellular Vesicles and Autophagy in Neuroimmune Disorders.
- Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
- A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
胆道闭锁
Biliary atresia2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 3 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。
这些数字背后的记录
牵头的论文3
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)3
- Passenger Lymphocyte Syndrome with Hepatic Sinusoidal Obstruction Syndrome in an Infant Following Living Donor Liver Transplantation: An Association or Coincidence?
- Sequential Operation of Kasai Portoenterostomy and Liver Transplantation is Recommended in Biliary Atresia Children for Better Outcomes: A Propensity Score Matching Analysis
- Simultaneous pancreaticoduodenectomy and liver transplantation for biliary atresia complicated by choledochal cyst
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 8 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
中文论文(未计入)1
早期论文(2016–2020 年)1
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
牵头的论文3
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 6 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 12 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07390123
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙
- 正在招募A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- 分期
- III期
- 开始
- 2025-07
- 登记号
- NCT06963827
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文6
- Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.
- Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
- Downregulation of PPARα mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells.
- A single-cell survey of the human glomerulonephritis.
- KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.
- Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
早期论文(2016–2020 年)3
- Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Progression in IgA Nephropathy.
- Contrast-enhanced ultrasonography for assessment of tubular atrophy/interstitial fibrosis in immunoglobulin A nephropathy: a preliminary clinical study.
- Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 17 篇,占 5.7%。
上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Biochemical Response and Clinical Outcomes in Patients With PBC
- 分期
- 未注明
- 开始
- 2026-02
- 登记号
- NCT07449793
年龄 18 岁 至 85 岁(登记的条件)
牵头:上海交通大学医学院附属仁济医院上海
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文17
- The phenotypic and functional characteristics of intrahepatic CD69+CD103+ tissue-resident MAIT cells in primary biliary cholangitis.
- B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis.
- Gut microbiome pattern impacts treatment response in primary biliary cholangitis.
- Osteoporosis and Primary Biliary Cholangitis: A Trans-ethnic Mendelian Randomization Analysis.
- Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.
- Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases.
- Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.
- MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
- Reply to: "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
- Intestinal microbiota in biliary diseases.
- Implications of gut microbiota in autoimmune liver diseases.
- A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.
- Morphological, Functional, and Tissue Characterization of Silent Myocardial Involvement in Patients With Primary Biliary Cholangitis.
- Immunologic Responses and the Pathophysiology of Primary Biliary Cholangitis.
- NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis.
- Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China.
- Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.
中文论文(未计入)3
早期论文(2016–2020 年)17
- Epigenetics of Primary Biliary Cholangitis.
- Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
- Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.
- Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis.
- Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?
- CTHRC1 expression in primary biliary cholangitis.
- [Clinicopathological analysis of anti-mitochondrial antibody negative primary biliary cholangitis-autoimmune hepatitis overlap syndrome].
- [Research advances of autoimmune liver diseases in 2018].
- Clinical analysis of liver transplantation in autoimmune liver diseases.
- The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7.
- Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.
- The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
- Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
- [Advances in the treatment of primary biliary cholangitis].
- [Research advances in autoimmune liver diseases in 2016].
- The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.
- A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Biochemical Response and Clinical Outcomes in Patients With PBC
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
- Early Identification of Myocardial Impairment in PBC
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 5 篇,占 5.0%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07387549
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
- Intestinal microbiota in biliary diseases.
- P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
- Implications of gut microbiota in autoimmune liver diseases.
- Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
中文论文(未计入)2
早期论文(2016–2020 年)10
- CTHRC1 expression in primary biliary cholangitis.
- [Research advances of autoimmune liver diseases in 2018].
- Clinical analysis of liver transplantation in autoimmune liver diseases.
- [Pathogenesis of immunoglobulin G4-related hepatobiliary disease].
- [Clinical observation of isolated immunoglobulin G4-related sclerosing cholangitis and immunoglobulin G4 sclerosing cholangitis combined autoimmune pancreatitis].
- [Research status and challenges in immunoglobulin G4-related hepatobiliary disease].
- Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.
- Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
- Comparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC/AIH and PSC alone.
- [Research advances in autoimmune liver diseases in 2016].
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
- Multicenter Observational Study of PSC and IgG4-SC in China
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
其他疾病
遗传性血管性水肿
Hereditary angioedema2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
联系这家医院
出示给工作人员或司机的院名卡
上海交通大学医学院附属仁济医院
Renji Hospital
上海
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。